ChemoCentryx, Inc. (NASDAQ:CCXI) Downgraded by Zacks Investment Research
ChemoCentryx, Inc. (NASDAQ:CCXI) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research report issued to clients and investors on Friday.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
A number of other research analysts have also issued reports on the stock. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Tuesday. BidaskClub lowered shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Thursday.
Shares of ChemoCentryx (NASDAQ:CCXI) traded down 2.83% on Friday, reaching $7.20. 453,172 shares of the company were exchanged. The company’s market cap is $350.68 million. The company’s 50-day moving average price is $9.61 and its 200 day moving average price is $7.71. ChemoCentryx has a 12 month low of $4.06 and a 12 month high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.02. The firm had revenue of $8.94 million for the quarter. On average, equities research analysts expect that ChemoCentryx will post ($0.90) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “ChemoCentryx, Inc. (NASDAQ:CCXI) Downgraded by Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/11/chemocentryx-inc-nasdaqccxi-downgraded-by-zacks-investment-research.html.
In other ChemoCentryx news, insider Petrus Bekker sold 76,013 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $9.95, for a total transaction of $756,329.35. Following the completion of the transaction, the insider now owns 65,963 shares in the company, valued at approximately $656,331.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 223,649 shares of company stock valued at $2,157,360. Company insiders own 26.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL raised its position in ChemoCentryx by 22.5% in the first quarter. BVF Inc. IL now owns 8,182,052 shares of the biopharmaceutical company’s stock valued at $20,373,000 after buying an additional 1,504,330 shares during the last quarter. Franklin Resources Inc. raised its position in ChemoCentryx by 22.4% in the first quarter. Franklin Resources Inc. now owns 2,165,397 shares of the biopharmaceutical company’s stock valued at $5,392,000 after buying an additional 396,900 shares during the last quarter. BlackRock Fund Advisors raised its stake in ChemoCentryx by 2.0% in the first quarter. BlackRock Fund Advisors now owns 1,279,222 shares of the biopharmaceutical company’s stock valued at $3,185,000 after buying an additional 25,382 shares in the last quarter. Vanguard Group Inc. raised its stake in ChemoCentryx by 1.1% in the second quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock valued at $11,345,000 after buying an additional 13,344 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in ChemoCentryx by 1.8% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,102,332 shares of the biopharmaceutical company’s stock valued at $8,929,000 after buying an additional 19,375 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.